Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Recruiting · NCT07140679 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT07140679 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Coherus Oncology, Inc. | 14 |
| Emory University | 393 |
| National Cancer Institute (NCI) | 3015 |
5 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory Decatur Hospital | Atlanta | United States | 1 |
| Emory Johns Creek Hospital | Johns Creek | United States | 36 |
| Emory Saint Joseph's Hospital | Atlanta | United States | 175 |
| Emory University Hospital Midtown | Atlanta | United States | 246 |
| Emory University Hospital/Winship Cancer Institute | Atlanta | United States | 299 |